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Summary
The research objectives was to establish pre-operative values of the tumor marker CA 15-3 in serum and to establish 
connection between serum level of the tumor marker CA 15-3 in patients with breast cancer with other prognostic factors 
for breast cancer (age, tumor size, lymph node status, histological grading, hormone receptor status). In this work, a retro-
spective study in 100 breast cancer patients who started their medical treatment in year 2007. on Department of Surgical 
Oncology, University Hospital for Tumors, Sestre milosrdnice Clinical Hospital Center, has been made.
The concentration of tumor marker CA 15-3 was measured in serum by immunochemical method. When breast cancer 
was diagnosed, 11 patients had elevated tumor marker CA 15-3, while 89 patients had CA 15-3 within the normal range 
(values ≤28 kUI/L were considered within the reference range and values >28 kUI/L were considered elevated). Patients who 
developed metastases had signifi cantly higher values of pre-operative tumor marker CA 15-3 and that patients died from 
the same disease (mean, CA 15-3=30.67 kUI/L) . High levels of CA 15-3 had patients with positive lymph nodes (status N3, 
mean CA 15-3=52,78). Results from this research shown that correlation between pre-operativne value tumor marker CA 
15-3 with age, ER expression, HER2 status and histologic grade were not found.
Elevated value of tumor marker CA 15-3 is at the time of diagnosis unfavorable prognostic factor, connected with 
other unfavorable prognostic factors. Justifi cation of this study was confi rmed by the value of preoperative tumor marker 
CA 15-3 in breast cancer patients and after determining its connection with other prognostic factors CA 15-3 indicates that 
is safer to extract subgroup of breast cancer patients in which metastases can be expected. As such, CA 15-3 can early focus 
on access to treatment by aggressive protocol.
KEY WORDS: breast cancer, CA 15-3, prognostic signifi cance
PROGNOSTIČKO ZNAČENJE TUMORSKOG BILJEGA CA 15-3 U BOLESNICA S RAKOM DOJKE
Sažetak
Cilj istraživanja bio je utvrditi predoperativne razine tumorskog biljega CA 15-3 u serumu te ustanoviti povezanost 
razine tumorskog biljega CA 15-3 kod bolesnica s rakom dojke s ishodom liječenja, te s drugim prognostičkim čimbenicima 
za rak dojke (dob, veličina tumora, status limfnih čvorova, histološki i hormonski status tumora). U ovom se radu izradila 
retrospektivna studija na uzorku od 100 bolesnica koje su započele liječenje zloćudnog tumora dojke na Zavodu za onko-
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lošku kirurgiju, Klinike za tumore, KBC Sestre milosrdnice tijekom 2007. godine. Koncentracija tumorskog biljega CA 15-3 
mjerena je u serumu imunokemijskom metodom.
U trenutku dijagnoze karcinoma dojke, 11 bolesnica imalo je povišen tumorski marker CA 15-3, dok je 89 bolesnica 
imalo vrijednosti CA 15-3 unutar granica normale (gdje su vrijednosti ≤28 kUI/L smatrane u granicama referentnih vrijed-
nosti a vrijednosti >28 kUI/L povišene). Bolesnice koje su razvile metastaze imale su značajno veće predoperativne vrijedno-
sti tumorskog biljega CA 15-3 te su iste imale i smrtni ishod liječenja (srednja vrijednost, CA 15-3=30.67 kUI/L ). Veće vrijed-
nosti CA 15-3 imale su i bolesnice s zahvaćenim limfnim čvorovima (status N3, srednja vrijednost CA 15-3=52,78 ). Poveza-
nost predoperativne razine tumorskog biljega CA 15-3 s dobi, statusom estrogenskih receptora, HER2 receptorom i 
histološkim gradusom nije nađena. Povišena vrijednost tumorskog biljega CA 15-3 je u trenutku dijagnoze nepovoljan 
prognostički pokazatelj, povezan s drugim nepovoljnim prognostičkim pokazateljima.
Ovo istraživanje je potvrdilo opravdanost određivanja predoperativne razine tumorskog biljega CA 15-3 kod bole-
snica oboljelih od raka dojke jer je nakon određivanja njegove povezanosti s ostalim prognostičkim pokazateljima ukazalo 
da taj tumorski biljeg sigurnije izdvaja podgrupu bolesnica kod kojih se može očekivati pojava udaljenih metastaza. Kao 
takav, CA 15-3 može rano usmjeriti na pristup liječenja prema agresivnijem protokolu.
KLJUČNE RIJEČI: karcinom dojke, CA 15-3, prognostičko značenje
percentage of cells in S phase, proteins related to 
degree of tumor invasive properties of tumors (ca-
thepsin D, plasminogen activators and nm23) and 
hormone receptors – estrogen (ER) and progester-
one (PR) receptors. Tumors with high level of these 
receptors are hormone-dependent tumors respon-
sive to hormonal therapy. Thus, for example ER+/
PR+ tumors respond to hormonal therapy in about 
75% of cases. Molecular markers, such as muci-
nous epithelium, oncogenes and tumor suppressor 
genes also need to be mentioned (6).
Determination of gene expression and intro-
duction of new molecular biology methods sheds 
a new light on hormone receptor – ER positive tu-
mors. Several subgroups could be determined 
within ER positive and negative tumors with dif-
ferent prognosis and response to hormonal thera-
py. For example, ER positive tumors (luminal 
type) could be subdivided into three subtypes ac-
cording to their expression which is related to the 
frequency of TP53 mutation (A,B and C) while ER 
negative tumors (basal) could be subdivided into 
tumors with HER2 expression and HER2 negative 
tumors.
Breast cancer treatment depends on tumor 
grade, tumor extension, tumor and host proper-
ties, and it could be local (surgery or radiation) or 
systemic.
Markers
In broader sense of the word, markers en-
compass all the ingredients and products of tumor 
cells that enable tumor to be detected (diagnosed), 
INTRODUCTION
Breast cancer is most common cancer site in 
women worldwide. In Europe, 464,000 new breast 
cancer cases a year are detected in women (13.4% 
new cancer cases in women) (1). In Croatia, 25,574 
new female cancer cases (26% of total new female 
cancer cases) were recorded in 2013, and 994 
(16.8%) of total female deaths are caused by breast 
cancer. Male breast cancer is rare. The male breast 
cancer incidence is 1-2 in 100 cancer cases (2).
Risk factors related to the breast cancer de-
velopment are numerous, including genetic, hor-
monal, nutritional and environmental.. Regard-
less of all available risk factor data, the said risk 
factors have not been confi rmed in 75% women 
with breast cancer (3).
The most recent classifi cation of invasive 
breast carcinoma based on biological characteris-
tics includes: Luminal A, Luminal B, HER2 posi-
tive and triple-negative breast carcinoma (4,5).
Determination of the so called prognostic fac-
tors is important for its multiple role: it renders 
the disease biology data, points to possible disease 
outcome in terms of survival probability or dis-
ease recurrence, could be used for therapy plan-
ning or point to specifi c sensitivity to a specifi c 
therapy agent.
The most important prognostic factors for 
breast cancer are tumor size and diff erentiation 
and histological grade (the most common is Bloom-
Richarson grading system with 3 prognostic gra-
des), histological type of tumor, axial node status 
(involvement), cell proliferation factors such as 
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classifi ed and its behaviour during treatment 
monitored. In narrower sense of the word, mark-
ers are products of tumor cells that can be mea-
sured in extracellular environment, primarily in 
bodily liquids. Determination of tumor marker 
concentration in serum is considered particularly 
important in modern tumor diagnostics and ther-
apy eff ect monitoring. Concentration of tumor an-
tigen in serum is determined by sensitive immu-
nochemical methods, enzyme-linked immunosor-
bent assay (ELISA) or turbidimetry. Data on serum 
level of markers is used as complementary meth-
od in making diagnosis, assessment of the disease 
extent, and for treatment eff ect monitoring (7).
 CA 15-3 is one of the fi rst prognostic breast 
cancer factors relying on circulating tumor cells. 
CA 15-3 is a glycoprotein, which occurus particu-
lary in the cells of mammary glands. Its concetra-
tion in blood may be measured in laboratory from 
semple of venous blood.
Preoperative value of this marker could be 
combined with other prognostic factors to predict 
outcome of the disease in patients with newly di-
agnosed breast carcinoma. However, it is particu-
larly clinically signifi cant for monitoring metastat-
ic disease response to chemotherapy (8).
In breast carcinoma diagnostics, elevated val-
ue of CA 15-3 tumor marker is an indication of lo-
cally advanced breast cancer and therefore faster 
recurrence and poorer treatment outcome (9,10).
CA 15-3 determined individually could have 
a prognostic signifi cance in newly diagnosed fe-
male breast cancer patients, and be a strong prog-
nostic indicator in patients with advanced breast 
cancer (10, 11).
Low sensitivity and specifi city of this marker 
rule it out as a marker for early breast cancer diag-
nosis. In patients diagnosed with cancer in early 
stage of the disease, CA 15-3 levels correspond to 
a large degree with CA 15-3 levels in healthy 
women or women with benign breast cancer. Ele-
vated CA 15-3 levels point to a metastatic disease, 
thus additional tests are necessary to exclude such 
a possibility. About 5-10% of women are diag-
nosed with advanced breast cancer. Although el-
evated CA 15-3 tumor marker levels are deter-
mined in the majority of patients with advanced 
breast cancer, its high concentrations might also 
be detected in case of some other types of ad-
vanced adenocarcinoma. Aside from breast can-
cer, advanced carcinoma that could result in ele-
vated CA 15-3 levels include ovarian, pancreatic, 
lung and intestinal cancer. Rarely, some non-ma-
lignant diseases such as chronic hepatitis, cirrho-
sis of the liver, sarcoidosis, megaloblastic anemia 
could cause elevated CA 15-3 levels (12,13). De-
pending on the determination method, and re-
agent and analyser manufacturer, normal levels of 
serum marker CA 15-3 for men and women is less 
than 25-30 kUI/L.
The aim of this study are to determine the 
preoperative serum CA 15-3 tumor marker levels 
and to establish correlation between the CA 15-3 
level in breast cancer patients and treatment out-
comes, and other breast cancer prognostic factors
SUBJECTS AND METHODS
Subjects
A retrospective study was made of 100 fe-
male patients who started their breast cancer 
treatment at the Oncological Surgery Department, 
University Hospital for Tumors, Sestre milosrd-
nice University Hospital Center in 2007. All the 
patients included in the study had operable breast 
carcinoma, namely subjects were patients with 
disease stage I-III.
The study was approved by the Ethics Com-
mitt ee of the Sestre milosrdnice University Hospi-
tal Center (No.: EP-6820/13-10).
The preoperative basic serum values of tu-
mor marker CA 15-3 and patients data, were re-
trieved from the University Hospital for Tumors 
archives keeping all the histories of the female pa-
tients. The data on the state of health of a part of 
patients regularly checked at the University Hos-
pital for Tumors was retrieved from the Universi-
ty Hospital for Tumors database, while the data 
on patient with fatal outcome was obtained from 
the database of the Croatian Institute of Public 
Health Cancer Registry.
Information on the state of health of other pa-
tients was obtained by telephone survey.
Methods
The CA 15-3 marker concentration was mea-
sured in serum obtained by centrifuging whole 
blood at 3,500 rpm for 10 minutes. The measuring 
was based on chemoluminiscence principle use, 
where reagent components are specifi cally de-
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signed antibodies lining paramagnetised micro 
particles. During the fi rst incubation, antigen from 
the sample (CA 15-3) bonds specifi cally to bound 
antibodies proportional to its presence in sample. 
During the secondary reaction, also referred to as 
indicator reaction, a conjugate (secondary anti-
body to which a marker of chemiluminiscent pro-
perties is bound) bonds to the formed At-Ag com-
plex. After excessive unbound conjugate is washed 
and magnetic separation of bound complex from 
micro particles carried out, in the end, a dramatic 
change of pH (addition of high molar NaOH) acti-
vates chemiluminiscence whose intensity is pro-
portional to antigen (CA 15-3) concentration in 
primary reaction. CA 15-3 concentration was mea-
sured by automated immunoassay analyser Ar-
chitect i2000SR manufactured by Abbott  (Abbott  
Laboratories, Abbott  Park, Illinois, USA). Reagents 
(Ca15-3 RGT;2K44-20), calibrator (CA 15-3 CAL; 
2K44-01)) and controls (Tumor Marker –MCC 
Lyophilised; 6E21-10) by the same manufacturer 
were used.
Statistical analysis
The data stored in spreadsheets was pro-
cessed using descriptive and inferential statistics 
methods.
Kaplan-Meier estimator of survival function 
and Nelson-Aalen estimator of risk function were 
used for descriptive survival analysis. Mean and 
median survival times with related limits were 
also calculated.
Cox regression for survival analysis was used 
in evaluation of predictive (prognostic) validity of 
CA 15-3 marker.
RESULTS
Characteristics of 100 patients involved in the 
study are given in Table 1.
In majority of patients (59) the smallest tu-
mor T1 (to 2 cm) was determined. In 38 patients 
tumor size was T2 (2-5cm), and 3 patients had tu-
mor larger than 5 centimetres. Axillary nodes (N0) 
were not aff ected in majority of patients (n=47), 
while 28 patients had lymph node status N1 (1-3 
positive lymph nodes), 16 patients had N2 (4-9 
positive lymph nodes), while in 9 patients more 
than 9 lymph nodes were positive. The majority of 
patients (57) had moderately diff erentiated tu-
mors (grade II), 15 patients had grade I and 28 pa-
tients had grade III tumors. As regards histologi-
cal diagnosis, carcinoma ductale invasivum was 
dominant (84 patients), while incidence of other 
carcinomas was lower (CLI 11, CMI 5 patients). 
Estrogen receptors were positive in the majority of 
patients (n=82), and 68 patients had progesterone 
receptor positive tumor. Incidence of breast can-
cer is present in elderly women (>50 years of age). 
Total 76 patients that developed breast cancer 
were older than 50 years, while 24 patients were 
younger than 50 years. HER2 positive tumor was 
diagnosed in 39 patients, and HER2 negative 
breast cancer was diagnosed in 61 patient.
At the time breast cancer was diagnosed, 11 
patients had elevated CA 15-3 marker, and 89 pa-
tients had CA 15-3 marker values within normal 
range (where values ≤28 kUI/L are considered as 
within the reference value range and values >28 
kUI/L as elevated). Mean preoperative value of 
CA 15-3 marker was 19.47 kUI/L.
Table 1. shows that CA 15-3 value was sig-
nifi cantly statistically diff erent if the patients were 
classifi ed by criterion N (p=0.01), where testing of 
diff erence in CA 15-3 level with regard to the 
lymph node status indicates that the patients with 
aff ected lymph nodes (status N3) had statistically 
signifi cantly higher CA 15-3 level (Kruskal-Wallis 
test); and PR (p=0.04) where the results also indi-
cated that the patients with negative progesterone 
receptors had statistically signifi cantly higher CA 
15-3 marker values (Mann-Whitney test).
Results of testing the diff erence in CA 15-3 
level with regard to the tumor size (T1-T4) indicat-
ed that the patients with tumor T3 (p=0.01) had 
signifi cantly higher preoperative value of CA 15-3 
marker (87.50 kUI/L) than the patients with T1 and 
T2 tumor (Kruskal-Wallis test).
Testing the diff erence in CA 15-3 level be-
tween T1 and T2 tumors (Mann-Whitney test) re-
sulted in marginal statistical signifi cance (p=0.055).
Correlation between CA 15-3 and tumor size 
expressed in centimetres is statistically signifi cant 
(p=0.002). Mean size of tumor in patients partici-
pating in the study was 2.2 cm. Patients with tu-
mor larger than 2.2 cm had higher values of CA 
15-3 marker compared to the patients with tumor 
smaller than average.
Results obtained by descriptive statistic meth-
od indicated that preoperative value of CA 15-3 
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marker and age is statistically insignifi cant (p=0.2). 
There is also no statistical signifi cance in CA 15-3 
level in patients under/over 50 years of age (Mann-
Whitney test).
No statistically signifi cant diff erence was de-
termined in measured CA 15-3 values in patients 
classifi ed using HG, ER, histological diagnosis 
and HER2 status.
Table 2. shows which therapy was adminis-
tered. Seventy-three patients were administered 
chemotherapy, eighty-one hormonal therapy and 
seventy-eight patients received radiation therapy. 
Combination of chemotherapy and hormonal 
therapy was administered to fi fty-six patients 
while the combination of chemotherapy, hormon-
al and radiation therapy was administered to for-
ty-seven patients.
Table 3. shows local recurrence in 4 patients, 
metastases in 9 patients, and fatal outcome in 11 
patients.
CA 15-3 value in the group of patients with 
metastases was statistically signifi cant (p=0.01) as 
compared with the group of patients without me-
tastases, namely the patients with metastases had 
higher preoperative level of CA 15-3 (30.67 kUI/L) 
Table 1.















II 57 16.93 p>0.05
III 28 22.57
ER
pos 82 18.48 0.1
neg 18 24.00
PR




CLI 11 22.82 p>0.05
CMI 5 14.00
AGE
<50 24 16.25 0.8
>50 76 20.49
HER2
pos 39 23.77 0.1
neg 61 16.72
Marker (preoperative level)
CA 15-3 < 28 kUI/L 89
CA 15-3 > 28 kUI/L 11
T, tumor size; N, lymph node status; HG, histological grade; ER, estrogen 
receptor; PR, progesterone receptor; HER 2, human epidermal growth 
 factor receptor 2; CA 15-3, tumor antigen 15-3; p, statistical signifi cance 
 determined by Kruskal-Wallis and Mann-Whitney test
Table 2.
ADJUVANT THERAPY ADMINISTERED










chemotherapy + hormonal 56
chemotherapy + hormonal + radiation 47
Table 3.
NUMBER OF PATIENTS WITH LOCAL RECURRENCE, 






yes 4 26.50 p>0.05
no 96 19.18
metastases
yes 9 30.67 0.01
no 91 18.36
exitus




than the patients without metastases (Mann-Whit-
ney Test).
CA 15-3 did not diff erentiate the patients 
with regard to the presence of local recurrence or 
exitus (p>0.5).
Cox regression for survival analysis did not 
show correlation between the patients who died 
and their age, tumor size, status of estrogen and 
progesterone receptors, HER2 status and CA 15-3 
level. Only development of metastases in patients 
was shown as signifi cant variable in fatal outcome 
of the treatment (p=0.04).
Graph 1. shows the survival curve for pa-
tients with metastases (Kaplan-Meier). Survival 
time is measured by moths.
DISCUSSION
A retrospective study was made of 100 fe-
male patients who started their breast cancer 
Graph 1. Kaplan-Meier survival curve
Table 4.
COX REGRESSION FOR SURVIVAL ANALYSIS
N = 100
Dependent variable: time (months)
Censored variable: exitus
Chi2 = 8.82264 df = 7 p = 0.26568
Beta Standard. Error t-value Exponent beta WaldStatist. p
Age 0.02414 0.028069 0.85994 1.024431 0.739491 0.389831
Tumor size 0.01041 0.146405 0.007108 1.010461 0.005052 0.943334
ER 0.062634 0.855409 0.73221 1.870744 0.536127 0.464048
PR -1.14444 0.712940 -1.60524 0.318403 2.576787 0.108452
HER2 0.73305 0.624799 1.17326 2.081422 1.376539 0.240700
Metastases 1.58006 0.770597 2.05044 4.855246 4.204293 0.040330
Preoperative CA 15-3 -0.00840 0.014560 -0.57692 0.991635 0.332831 0.564001
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treatment at the Oncological Surgery Department, 
University Hospital for Tumors, Sestre milosrd-
nice University Hospital Center in 2007 and were 
followed up for 5 years. Preoperative values of CA 
15-3 marker were determined, and correlation be-
tween its level and treatment outcomes and other 
breast cancer prognostic factors was analysed.
CA 15-3 is the tumor marker routinely used 
in breast cancer diagnosis and monitoring of treat-
ment results. Determination of its value in initial 
treatment stage when diagnosis is made is an al-
most standard approach. CA 15-3 is one of the 
fi rst prognostic breast cancer factors relying on 
circulating tumor cells and when determined in-
dividually it has prognostic value. (9,11) Its prog-
nostic value in combination with other tumor 
markers is frequently studied. In breast cancer de-
tection, elevated CA 15-3 marker levels are an in-
dication of locally advanced carcinoma and conse-
quently faster recurrence and fatal outcome of the 
disease (14).
The patients included in this study who de-
veloped metastases had elevated values of CA 
15-3 (p=0.01) and consequentially fatal treatment 
outcome. The results obtained correspond with 
results of other studies (15,16).
The results presented in this study also dem-
onstrate correlation between the preoperative CA 
15-3 marker levels and tumor size (less than 2.2 
cm). An average tumor size of the studied group 
was more than 2.2 cm. The patients with tumor 
larger than average had statistically higher (pre-
operative) level of CA 15-3.
The patients with tumor between 5 and 10 cm 
(T3 tumors) had statistically signifi cantly higher 
CA 15-3 marker level. However, because of a small 
number of patients in the group (2 patients with 
T3 tumor and one patient with T4 tumor), the re-
sult is diffi  cult to interpret. Also, testing of diff er-
ence between T1 and T2 tumors with regard to CA 
15-3 level has not shown statistical signifi cance.
Patients with N3 tumor had signifi cantly 
higher values of CA 15-3 marker.
Results obtained by Park et al. and Moazzezy 
et al. are similar. In their study they established a 
correlation between CA 15-3 (and CEA) level and 
tumor size (>5cm) and lymph node status (more 
than 4 nodes involved).(10,16) Duff y et al. got the 
results showing a signifi cantly higher CA 15-3 
marker levels in patients with larger tumors and 
patients with positive lymph nodes, unlike the pa-
tients with N0 status (14).
Additionally, the conducted study detected 
no correlation between the preoperative level of 
CA 15-3 marker and age, estrogen receptor status, 
HER2 receptor or histological grade. The same re-
sults were obtained by Park et al. in their study. 
(10) Ebeling et al. study shows that tumor size, 
lymph node status, histological grade and hor-
monal status are prognostically signifi cant (9). 
Duff y et al. have not established a correlation be-
tween the CA 15-3 level with estrogen positive or 
negative receptors (which corresponds with the 
results of this study). On the other hand, their ob-
tained results, of CA 15-3 level, was signifi cantly 
higher in patients aged 50 years and older, while 
in our study the diff erence in CA 15-3 levels in pa-
tients older/younger than 50 years of age was not 
statistically signifi cant (14).
The study result indicate correlation between 
the negative progesterone receptor levels and CA 
15-3 level (considerably higher). The result is dif-
fi cult to interpret since negative progesterone re-
ceptors do not have as signifi cant prognostic value 
as negative estrogen receptors. However, when 
estrogen receptors are positive, negative proges-
terone receptors often have poorer prognostic sig-
nifi cance (17,18).
Multivariate analysis did not statistically in-
dicate correlation of CA 15-3 and traditional prog-
nostic indicators with treatment outcome. As ex-
pected, only development of metastases was the 
statistically signifi cant indicator of fatal outcome 
of patient treatment. Since the study dealt with 
early breast carcinoma, the result complies with 
the results of other studies where the most diffi  -
cult task is to single out a subgroup of patients 
with poorer prognosis who will benefi t from ag-
gressive adjuvant therapy (18,19,20).
As regards this study, it should be under-
scored that the patients who developed metasta-
ses had signifi cantly higher preoperative values of 
CA 15-3 marker and fatal outcome of treatment. 
Higher CA 15-3 values were recorded in patients 
with larger tumors (>2.2cm), aff ected lymph nodes 
(status N3) and in patients with negative proges-
terone receptors.
In diagnostic process, elevated values of CA 
15-3 tumor present an unfavourable prognostic 
indicator and they are correlated with other unfa-
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vourable prognostic indicators (such as tumor 
size, lymph node status, hormonal status).
The present study confi rmed that determina-
tion of preoperative level of CA 15-3 marker in 
breast cancer patients is justifi ed since, once its 
correlation with other prognostic indicators is es-
tablished, it serves for safer singling out of patient 
subgroup expected to develop distant metastases. 
As such, CA 15-3 could result in early decision of 
treatment under more aggressive protocol.
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